Bellicum Pharmaceuticals Culture Company

Mr. David M. Spencer, Ph.D. Co-founded Bellicum Pharmaceuticals, Inc. in July 2004 and has also been its Chief Scientific Officer since November 2011. Mr. Spencer served as Director of Bellicum Pharmaceuticals, Inc. until September 2004. Mr. Spencer is Associate Professor of Immunology, Baylor College of Medicine. Recently he was awarded the Michael E. DeBakey Excellence in Research Award at Baylor College of Medicine. Dr. Spencer earned his Ph.D. from the Massachusetts Institute of Technology and completed his postdoctoral degree at Stanford University.

Dr. Annemarie Moseley, Ph.D., M.D. has been Consultant of Bellicum Pharmaceuticals, Inc. since July 31, 2017. Dr. Moseley served as the Chief Operating Officer and an Executive Vice President of Clinical Development at Bellicum Pharmaceuticals, Inc. from November 2012 to July 31, 2017 and from April 2015 to July 31, 2017 respectively. She served as Senior Vice President of Clinical Development and Regulatory Affairs at Bellicum Pharmaceuticals, Inc. since October 2011 until April 2015. She serves as Chairman and Chief Executive Officer of REPAIR Technologies, Inc. From July 2005 to September 2011, she served as Chief Medical Officer at REPAIR Technologies, Inc., a private biotechnology company. She has over 20 years of industry experience in translational medicine and clinical development of stem cell therapies, immunotherapies, biological devices and combination products, including overseeing the first late-stage Graft versus Host Disease study in patients who underwent hematopoietic stem cell transplant. She served as President, Chief Executive Officer and a Director of Osiris Therapeutics, Inc., She participated in extensive fundraising and partnering activities. In 2002, She founded Cognate Therapeutics, Inc. with Toucan Capital and as President and Chief Executive Officer led the development of a cellular therapy for glioblastoma. She has acted as a strategic consultant on cellular therapies to a number of medical device companies and as commercialization advisor to the Canadian Stem Cell Network. She served as Vice President of Clinical Research for Applied Immune Sciences from 1992 to 1995, overseeing clinical development of stem cell therapies for HIV, bone marrow transplantation and gene therapy. Subsequently, in her role as Director of Clinical Gene Therapy at SyStemix/Novartis, She managed a stem cell-based HIV gene therapy program. In 1997, Dr. Moseley joined Osiris Therapeutics as Senior Vice President of Clinical and Regulatory affairs, leading development activities for mesenchymal stem cell-based products in oncology, orthopaedics, cardiovascular and lysosomal storage disorders. She served as a Director of Sernova Corp. since November 2009 to June 2011 and previously served as a its Business Advisory Board from August 2009 to until June 2011. Dr. Moseley received her B.S. and M.S. from the University of Texas at Arlington and received her Ph.D. in Physiology and Biochemistry from Utah State University. She received her M.D. from Baylor College of Medicine where she completed an internal medicine residency and a genetics fellowship.

Mr. Thomas J. Farrel, also known as Tom, has been a Consultant of Bellicum Pharmaceuticals, Inc. since January 31, 2017. Mr. Farrel served as the President of Bellicum Pharmaceuticals, Inc. from November 2011 to January 31, 2017 and served as its Chief Executive Officer from February 2006 to January 31, 2017. Mr. Farrel was an Entrepreneur-In-Residence at PTV Healthcare Capital. He has successful entrepreneurial and operational track record in the life science and engineering industries. Previously, he founded Cylene Pharmaceuticals Inc. in early 1998, serving as the President and Chief Executive Officer until 2003 and Chief Operating Officer and Chief Financial Officer until 2005. During his tenure, Cylene raised $33 million in venture capital financing and successfully discovered and advanced a first-in-class anticancer agent, CX-3543, into clinical trials. Prior to this, Mr. Farrel implemented and supported a variety of pioneering business incubation programs at the IC2 Institute in the Technology Marketing Group, providing technology marketing, business planning and commercialization expertise in Austin, Texas, designed to foster high tech and life science start up company formation around federal labs and research universities, based on the award winning Austin Technology Incubator model. Previously, he worked in Europe and the United States as an Engineer for Houston-based Cooper Cameron, where he designed and developed a number of products and systems that are still successfully marketed worldwide. He has been a Director of Bellicum Pharmaceuticals, Inc. since April 2007. He holds an M.B.A. from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar in the top 10% of the class of 1993 and also holds a B.A. in Engineering from the University of Cambridge in 1984, becoming a Chartered Engineer in 1987, which he practiced for seven years..

Mr. Alan A. Musso, C.P.A., C.M.A., has been the Chief Financial Officer and Treasurer at Bellicum Pharmaceuticals, Inc. since November 2014. Mr. Musso has over 25 years of biotechnology and pharmaceutical industry experience in both large and emerging growth companies, including capital raising, corporate partnering, finance, strategy and the financial stewardship of publicly-traded companies. He served as the Chief Financial Officer, Senior Vice President of Finance & Administration, Treasurer and Assistant Secretary at Catalyst Biosciences, Inc. until 2014. He served as the Chief Financial Officer and Treasurer of Targacept, Inc. from February 2002 to November 18, 2014 and its Senior Vice President of Finance & Administration from March 2010 to November 18, 2014. He served as an Assistant Secretary of Targacept, Inc. since June 2007. He served as Principal Accounting Officer of Targacept, Inc. He served as Vice President of Targacept, Inc. from February 2002 to March 2010. He served as Secretary of Targacept, Inc. since February 2002. He served as the Chief Financial Officer of Cato Research Ltd. He served as the Chief Financial Officer and Vice President of Osiris Therapeutics Inc. from February 2001 to February 2002. He served as the Chief Financial Officer of Cato Research & Cato Holding Company from April 1997 to February 2001. He served as the Chief Financial Officer of Vascular Genetics Inc. from October 1997 to February 2000. He worked at Pfizer Inc. from April 1989 to December 1994, first as a Senior Auditor and then as a General Accounting Manager for one of Pfizers manufacturing facilities. He is a Certified Public Accountant and a Certified Management Accountant. Mr. Musso received a B.S. in Accounting from Saint Mary's College of California and a Master's Degree from the American Graduate School of International Management in Glendale, Arizona.

Dr. Gregory S. Naeve, also known as Greg, Ph.D. has been Chief Business Officer of Bellicum Pharmaceuticals, Inc. since August 21, 2017. Dr. Naeve was a Principal at The Column Group LLC. Dr. Naeve joined Bellicum from Pfizer where he served as the ImmunoOncology & Cell Therapy Lead for Pfizer''??s External Research and Development Unit. Previously, Dr. Naeve was an independent Consultant assisting early stage life science companies in the San Diego region. Dr. Naeve was previously the President and Chief Scientific Officer at Parallax Biosystems, which he had co-founded. Prior to Parallax, Dr. Naeve held positions at Neurocrine Biosciences and Amgen, working to develop new therapies for neurodegenerative disorders. He received a Ph.D. in Biochemistry from the University of Southern California. He holds B.S. in Biochemistry and Biological Sciences from Colorado State University.

Dr. Alan K. Smith, Ph.D. has been Executive Vice President of Technical Operations at Bellicum Pharmaceuticals, Inc. since May 16, 2017. Dr. Smith served as an Senior Vice President of Manufacturing at Bellicum Pharmaceuticals, Inc. since October 29, 2015 until May 15, 2017. Dr. Smith serves at Vericel Corporation. He served as Vice President of Research & Development and Cellular Therapeutics at LifeNet Health. He served as President of Cognate BioServices, Inc. (formerly Cognate Therapeutics, Inc) since January 2004 and served as its Chief Executive Officer. Dr. Smith served as President and Chief Operating Officer of Theradigm, Inc. He has over 30 years of experience in cellular therapeutics, during which time he served in various leadership roles in Research and Development, Manufacturing and Quality. He served as Chief Operating Officer of Cognate BioServices, Inc. since January 2004. He joined Cognate BioServices in 2002. Prior to joining Cognate, Dr. Smith served as Chief Operating Officer and Senior Vice President of Research & Development at Osiris Therapeutics where he held responsibilities for manufacturing, operations, facilities and research and development and also played a key role in devising clinical and regulatory strategies. From 1995 to 2000, he served as Vice President of Research at Aastrom Biosciences, Inc., where he was responsible for development of processes for ex vivo expansion of bone marrow, umbilical cord blood, T-cells, dendritic cells and other cell types for therapeutic use. Dr. Smith served as Vice President for Geneic Sciences, a wholly owned subsidiary of Titan Pharmaceuticals, Inc. During his tenure with Titan he led development of cell therapy processes to effect recipient tolerization to solid organ and allogenic bone marrow transplants and implantation of cells for the treatment of Parkinson's disease. From 1988 to 1994, Dr. Smith was at Baxter Healthcare Corporation, where he served as Director of Cell Separation Research and Development, Immunotherapy Division. Prior to joining Baxter, Dr. Smith held various management positions at BioSpecific Technologies, Inc. and HyClone Laboratories. He serves as a Member of the Board of Directors of Chata Biosystems of Fort Collins. Dr. Smith is an Adjunct Professor in the Department of Biology and Molecular Cell Biology at Eastern Virginia Medical School and has previously held adjunct professorships at California State University Long Beach and Utah State University. He received a Ph.D. in Biochemistry from Utah State University. Dr. Smith earned his Bachelor of Science in Chemistry at Southern Utah State College.

Mr. Ken Moseley, J.D. has been a Senior Vice President and General Counsel at Bellicum Pharmaceuticals, Inc. since January 2015 and has also been its Corporate Secretary since February 2012. Mr. Moseley served as the Vice President of Intellectual Property & Legal Affairs at Bellicum Pharmaceuticals, Inc. since December 2011 until January 2015. He served as General Counsel at Cognate BioServices, Inc. from February 2002 to March 2009. He has over 15 years of biotech patents and licensing experience. Prior to Cognate in 2002, he served as Vice President of Business Development & Patents at Osiris Therapeutics, Inc. and he served as the Director of Intellectual Property at SyStemix, a Novartis company. From March 2009 to September 2011, he served as General Counsel at REPAIR Technologies, Inc., a private biotechnology company. He served as Director of Intellectual Property for Applied Immune Sciences, a Rhone-Poulenc Rorer company. Mr. Moseley is a registered patent attorney and a member of the California and Texas Bars. Mr. Moseley received a JD and a BS in Biophysical Chemistry from the University of Houston and a BA from Rice University.

Alan Smith serves as the Executive Vice President, Technical Operations of Bellicum Pharmaceuticals, Inc.. Alan started at Bellicum Pharmaceuticals, Inc. in October of 2015. Alan is currently based in the Houston, Texas Area.